Provided by the Academy for Continued Healthcare Learning
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.
Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease. Despite advances in the management of IPF and frequent interactions with varying members of the multidisciplinary management team, patients with IPF report frustrations and significant emotional consequences of their disease. Clinicians involved in the care of patients with IPF require education on rapid advances in pharmacologic and nonpharmacologic approaches to provide evidence-based care that helps patients live longer and experience improved quality of life. This educational activity is Module 1 of two 30-minute digital classroom activities to engage clinicians and ensure an effective educational activity. A patient education activity has been developed as well to help bridge the communication gap between clinicians and patients, while providing an educational resource specific for the patient and caregiver.
This educational activity is designed for pulmonologists, respiratory nurses, respiratory therapists, and other clinicians interested in treatment advances for patients with IPF.
Upon completion of this activity, participants will be able to:
Discuss the impact of IPF on patient quality of life over the disease course
Describe benefits of a multidisciplinary approach over the course of IPF
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Kevin R. Flaherty, MD, MS Professor of Medicine Pulmonary/Critical Care University of Michigan Ann Arbor, MI
Dr. Flaherty discloses the following: Consultant: Boehringer-Ingelheim and Genentech
Imre Noth, MD Professor of Medicine Director, Bronchoscopy Director, Interstitial Lung Disease Program The University of Chicago Medicine Chicago, IL
Dr. Noth discloses the following: Advisory Board, Honoraria Recipient and Speakers Bureau: Boehringer-Ingelheim and Genentech
Amy L. Olson, MD, MSPH Assistant Professor Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health Denver, CO
Dr. Olson discloses the following: Advisory Board: Boehringer-Ingelheim Speakers Bureau: Genentech
Accredited Provider Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Katlyn Cooper Program Manager, ACHL email@example.com